China’s Alzheimer’s Surge Spurs Race for Early Detection and New Therapies: lzheimer’s disease is poised to become one of China’s most significant public-health challenges, with nearly 30% of global dementia patients already living there and projections suggesting tens of millions more by mid-century. In response, China is accelerating investment in screening, diagnosis, and treatment, while expanding clinical trials and recruiting top scientists from abroad. Researchers are pursuing diverse strategies, from drugs targeting brain-derived neurotrophic factor pathways and compounds rooted in traditional Chinese medicine to experimental surgical approaches aimed at improving brain waste clearance. At the same time, large genetic databases and biomarker studies are advancing earlier detection—potentially identifying the disease years before symptoms appear. Although funding still trails the United States, the scale and speed of China’s research effort are drawing global attention and positioning the country as a rising force in Alzheimer’s science. (Nature)

AI “Digital Twins” Take Aim at Diabetes and Obesity: A growing corner of digital health is trying to compete with GLP-1 drugs using something more behavioral than pharmaceutical: AI “digital twins” built from wearable and biometric data. WIRED reports on Twin Health, a program that ships participants a kit (including a continuous glucose monitor, blood pressure cuff, smart scale, and fitness tracker) and uses those streams to model a person’s metabolism and predict how food, activity, sleep, and stress may shift blood sugar and weight over time. Users log meals (photos, scans, voice), receive personalized prompts (like walking after eating), and can message human coaches. The pitch: earlier, data-driven interventions could reduce meds, improve glycemic control, and sustain weight loss—while saving employers money. (WIRED)

Coffee or Tea and Dementia Risk – A “Sweet Spot” Shows Up in Long Follow-Up Data: A large, decades-long analysis highlighted by Health suggests a modest daily caffeine habit may correlate with better brain outcomes. Drawing on repeated diet data and up to 43 years of follow-up from major U.S. cohorts, researchers observed that people who drank the most caffeinated coffee had a lower dementia risk than those with minimal caffeine intake, with the strongest association around two to three cups per day. Caffeinated tea showed a similar pattern at roughly one to two cups daily, without clear added benefit beyond that range. The piece emphasizes the key caveat: observational links can’t prove causality, and lifestyle differences may still matter even after adjustments. Still, the findings sharpen the question of whether caffeine itself contributes to resilience via inflammation pathways, vascular effects, or metabolic health. (Health)

HIIT Over 65: Small Changes, Potentially Meaningful Payoffs: High-intensity interval training (HIIT) is often marketed as a younger person’s game, but a research synthesis discussed by Health argues it may confer distinct body-composition advantages for older adults, too. The review, published in Maturitas, compared higher-intensity programs with more moderate exercise in adults over 65 and found HIIT tended to preserve more lean mass while also nudging body fat percentage downward. The article notes the magnitude of change was modest and the practical message isn’t “everyone must do HIIT,” but rather that—when medically appropriate and feasible—older adults may benefit from some higher-intensity work to counter two common aging trends: rising fat mass and declining muscle. It also underscores sensible guardrails: individualized programming, gradual progression, and attention to joint health and cardiovascular risk. (Health)

Longevity and Movement: Even “Small” Activity Shifts May Matter: A Harvard Health piece spotlights evidence that modest changes in physical activity can meaningfully move the needle on lifespan—especially if they replace sedentary time. The article frames a practical, non-intimidating takeaway: you don’t need to become an endurance athlete to benefit, and incremental increases (more walking, more frequent bouts of movement) may be associated with better longevity outcomes. It also highlights a recurring theme across the exercise literature: consistency beats heroics, and “activity snacks” spread through the day can complement longer workouts. While the post is written for a general audience, it points readers toward the underlying epidemiology logic—comparing groups across activity levels and estimating how shifting from low to higher activity could change risk. For readers trying to translate the science into behavior, the message is clear: start small, repeat often, and build. (the-scientist.com)

Medicare Advantage “Forced Disenrollment” Risks Grow as 2026 Plan Exits Loom: A new JAMA research letter focuses on a disruption many Medicare Advantage enrollees rarely face at scale: being forced out of a plan when it exits a market. The authors note Medicare Advantage enrollment has climbed steadily for two decades and plan availability has expanded sharply in recent years, which has made market exits—and the downstream churn they trigger—feel less common. But reports of insurers pulling back for 2026 raise the stakes. The letter frames forced disenrollment as more than a paperwork headache: switching plans can mean sudden provider-network changes, altered benefit designs, and loss of supplementary benefits that people rely on. The upshot is a policy and consumer-protection question for 2026: how big will the disruption be, and which beneficiaries are most exposed to involuntary switching? (JAMA Network)

RIF Reversal at NIOSH: A Win for Worker Health With a Recovery Hangover: The Scientist reports that many employees are returning after a reversal of workforce reductions at NIOSH, the U.S.’s primary federal agency dedicated to worker health and safety. The headline outcome sounds straightforward—scientists and staff back on the job—but the article emphasizes the harder, less visible part: the interruption itself can damage momentum. Paused studies, disrupted timelines, fractured collaborations, and the practical work of restarting projects (especially those involving field work, lab pipelines, or long-running surveillance) may create lasting drag. The piece also frames a broader public-health implication: worker-safety research often functions like infrastructure—quiet when it’s working, painfully noticeable when it’s weakened. Even with staff returning, NIOSH may face hurdles rebuilding operational capacity, restoring confidence, and catching up on the research and guidance that support industries nationwide. (the-scientist.com)

A Clinical “Nudge Engine”: LLMs Read Radiology Notes to Catch Missed Follow-Ups: Radiology Business covers a healthcare workflow problem with real safety consequences: radiologists often recommend follow-up imaging, but patients can fall through the cracks when those recommendations aren’t reliably flagged and acted on. In one health system, researchers tested a large language model designed to read radiologists’ free-text notes and identify follow-up recommendations, strengthening internal processes used to trigger reminders and scheduling. The report points to a NEJM Catalyst study and highlights why this is more than an administrative upgrade: missed follow-ups can delay diagnosis, while consistent follow-through can improve outcomes and reduce downstream costs. The appeal of LLMs here is pragmatic—language-heavy tasks are where automation can be most immediate—yet the article also signals the implementation reality: models must integrate cleanly into clinical systems, minimize false alarms, and prove they improve adherence without adding new burdens. (Radiology Business)

Dream Control Moves From Sci-Fi Toward Lab Reality: New Atlas reports on an experiment exploring whether lucid dreaming can be guided—not for thrills, but to test the old advice to “sleep on a problem.” Researchers recruited 20 experienced lucid dreamers—people who can recognize they’re dreaming and sometimes influence the dream—and probed whether dream content could be steered in ways that support problem-solving. The article situates the study alongside other recent work suggesting lucid dreaming may have therapeutic potential for conditions like PTSD and Parkinson’s disease, and it references prior demonstrations that limited two-way communication between lucid dreamers and researchers is possible during sleep. Importantly, this isn’t mind control: it’s controlled prompting and structured experimentation around a fragile mental state. But it does point to an emerging toolkit for studying consciousness and cognition in vivo—while people are asleep, mid-dream, yet still partially self-aware. (New Atlas)

Hepatitis B Trial Halted in Guinea-Bissau After Safety Signal: Reuters reports that a hepatitis B vaccine trial in Guinea-Bissau was stopped after investigators identified a safety concern, underscoring both the promise and the fragility of clinical research in real-world settings. The halt illustrates how vaccine development is governed by predefined stopping rules and ongoing monitoring designed to protect participants, even when a trial addresses a major global health burden. The article describes the trial’s suspension as a procedural intervention—pausing enrollment and/or dosing while the signal is investigated—rather than a final verdict on a product’s viability. It also highlights why transparent communication matters: safety reviews can quickly fuel rumors, but they’re also evidence that oversight systems are functioning. The broader takeaway is that “stopped” can mean many things in clinical research, from temporary caution to an endpoint—depending on what subsequent analysis finds. (Reuters)

CDC Cancels Vaccine Adviser Meeting, Raising Questions About Policy Continuity: Reuters reports that the CDC’s vaccine advisory committee meeting scheduled for late February (Feb. 25–27) will not be held and no new date was announced at the time. The Advisory Committee on Immunization Practices (ACIP) plays an outsized role in U.S. vaccination policy: its recommendations historically guide insurance coverage, school requirements, and how clinicians counsel patients. The report situates the cancellation within a larger period of upheaval in federal vaccine policy and governance, including leadership changes and legal challenges. It also notes concerns voiced by medical groups that disruptions to ACIP’s work could affect vaccination rates and create confusion for states, insurers, and clinicians who plan around the committee’s schedule and outputs. Even if the meeting is rescheduled, the immediate impact is uncertainty—precisely where public health systems typically prefer predictability. (Reuters)

Hospitals Fighting Measles Face a Data-and-Coordination Problem: KFF Health News reports from the front lines of a major measles surge, describing how hospitals and clinicians are coping with outbreak conditions while confronting a practical obstacle: incomplete visibility into where cases are showing up, how fast they’re spreading, and what resources are needed day to day. The piece notes that one South Carolina county has logged more than 900 cases in the current outbreak, and it reiterates why measles is uniquely punishing operationally—high contagiousness and the ability of the virus to linger in the air for up to two hours after an infected person leaves a room. That combination raises the stakes for rapid isolation, staff protection, and clear communication across facilities. The article frames measles response as not only a vaccination story, but a systems story: surveillance, reporting norms, hospital coordination, and the messy logistics of managing an airborne threat in real time. (KFF Health News)

Zoonosis Best Supported, but Key Data Gaps Keep COVID Origins Unresolved: Twenty-three former members of WHO’s Scientific Advisory Group for the Origins of Novel Pathogens (SAGO) summarize their June 2025 assessment of how SARS-CoV-2 entered humans. They argue that the strongest peer-reviewed evidence still points to a zoonotic origin, anchored by epidemiological links to Wuhan’s Huanan Seafood Market, environmental sampling that detected two early viral lineages, and the presence of susceptible wildlife species previously sold there. They find the “imported frozen goods” hypothesis unsupported by available evidence. For lab-related scenarios, the authors stress that much of the information needed for a rigorous evaluation—such as detailed biosafety records and staff health data—has not been shared, leaving uncertainty. They call for sustained animal/human surveillance, better biosafety standards, and transparent data release to enable unbiased investigation. (Nature)